Skip to main content
New Year’s Sale — Build a balanced news diet with 40% off Vantage
Get Started
SubscribeLogin
Published • loading... • Updated

MindRank Initiates Phase III 'MOBILE' Trial for MDR-001: an Oral GLP-1RA Small Molecule Engineered with AI

Summary by Financial Post
"As a biased-selective GLP-1 receptor agonist, MDR-001 not only promotes cAMP messenger release when acting on the GLP-1 receptor but also selectively recruits beta-arrestin 2," remarked Professor Linong Ji. "In the 24-week study, it demonstrated excellent weight loss efficacy while providing additional benefits in uric acid reduction and hepatic function measures improvement. The MDR-001 group showed a mean uric acid reduction of 57.7 µmol/L, a…

3 Articles

Cambridge TimesCambridge Times
+2 Reposted by 2 other sources
Lean Left

MindRank Initiates Phase III “MOBILE” Trial for MDR-001: an Oral GLP-1RA Small Molecule Engineered with AI

MDR-001 progressed from program discovery to Phase III in just 4.5 years, much faster than traditional development cycles.Phase IIb data demonstrated 10.3% mean weight reduction at Week 24 with a best-in-class safety potential (0.8% TEAE-related discontinuation rate).MDR-001’s unique biased-selective mechanism…

·Cambridge, Canada
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 67% of the sources lean Left
67% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Hamilton Spectator broke the news in Hamilton, Canada on Tuesday, January 6, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Artificial Intelligence icon

Artificial Intelligence

Cambridge, Ontario icon

Cambridge, Ontario

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal